Ultragenyx Pharmaceutical Inc
RARE
Company Profile
Business description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Contact
60 Leveroni Court
NovatoCA94949
USAT: +1 415 483-8800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
1,276
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,754.70 | 49.70 | 0.57% |
| CAC 40 | 7,236.89 | 1.78 | 0.02% |
| DAX 40 | 19,933.62 | 307.17 | 1.57% |
| Dow JONES (US) | 44,782.00 | 128.65 | -0.29% |
| FTSE 100 | 8,312.89 | 25.59 | 0.31% |
| HKSE | 19,702.99 | 152.70 | 0.78% |
| NASDAQ | 19,403.95 | 185.78 | 0.97% |
| Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
| NZX 50 Index | 13,093.18 | 21.50 | -0.16% |
| S&P 500 | 6,047.15 | 14.77 | 0.24% |
| S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
| SSE Composite Index | 3,378.81 | 14.82 | 0.44% |